Time to onset of efficacy with targeted preventative migraine therapy

At EAN 2022, Cristina Tassorelli, Professor of Neurology, University of Pavia, Italy, discussed how in general, newer, migraine-specific drugs for symptom prevention are effective at reducing number of headache days within 1 or 2 weeks following initiation, or even sooner in some patients. This fast onset means a more rapid improvement in a patient’s quality of life. In patients where their prescribed medication takes a number of months until there is a preventative effect, the chance that they remain adherent is decreased.


EAN : European Academy of Neurology 

Disclaimer: The video represent the opinion of the speaker. Lundbeck does not recommend the use of drugs outside of its registered indications. Please always consult the Summary of Product Characteristics.

BE-NOTPR-0308, approval date : 05.2023

You are leaving Progress in Mind
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intended for health care professionals.
All the information included in the Website is related to diseases, investigations and existing or potential treatment options and, therefore, directed to health professionals . The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Register for access to Progress in Mind in your country